Zucker Diabetic Fatty rats exhibit hypercoagulability and accelerated thrombus formation in the Arterio-Venous shunt model of thrombosis

Thrombosis Research

Volumn 134, Issue 2, 2014, Pages 433-439

  Shang, Jin ^a   Chen, Zhu ^a   Wang, Min ^a   Li, Qiu ^a   Feng, Wen ^a   Wu, Yangsong ^a   Wu, Weizhen ^a   Graziano, Michael P ^a   Chintala, Madhu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Coagulation; Platelet reactivity; Rat; Thrombin generation; Thrombus formation; Type 2 Diabetes

Indexed keywords

ADENOSINE DIPHOSPHATE; APIXABAN; COLLAGEN; DAPAGLIFLOZIN; GLUCOSE; PROTEINASE ACTIVATED RECEPTOR 4; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; GLUCOSIDE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENETIC REGULATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPERCOAGULABILITY; MALE; NONHUMAN; PLATELET REACTIVITY; PRIORITY JOURNAL; RAT; SHUNT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOGENICITY; TREATMENT OUTCOME; ZUCKER DIABETIC FATTY RAT; ANIMAL; BLOOD; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; DRUG EFFECTS; THROMBOPHILIA; THROMBOSIS; ZUCKER RAT;

ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; BENZHYDRYL COMPOUNDS; BLOOD COAGULATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FACTOR XA INHIBITORS; FEMALE; GLUCOSIDES; HYPOGLYCEMIC AGENTS; PLATELET AGGREGATION; PYRAZOLES; PYRIDONES; RATS; RATS, ZUCKER; THROMBOPHILIA; THROMBOSIS;

EID: 84905082673     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.04.008     Document Type: Article

References (42)

1. P.L. Gross, and J.I. Weitz New antithrombotic drugs Clin Pharmacol Ther 86 2009 139 146
2. P. Fumelli, F. Romagnoli, G. Carlino, C. Fumelli, and M. Boemi Diabetes mellitus and chronic heart failure Arch Gerontol Geriatr 23 1996 277 281
3. M.C. Alessi, and I. Juhan-Vague Metabolic syndrome, haemostasis and thrombosis Thromb Haemost 99 2008 995 1000
4. N. Vazzana, P. Ranalli, C. Cuccurullo, and G. Davi Diabetes mellitus and thrombosis Thromb Res 129 2012 371 377
5. D.J. Angiolillo Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions Diabetes Care 32 2009 531 540
6. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J.M. Friedman Positional cloning of the mouse obese gene and its human homologue Nature 372 1994 425 432
7. H. Chen, O. Charlat, L.A. Tartaglia, E.A. Woolf, X. Weng, and S.J. Ellis et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice Cell 84 1996 491 495
8. M.L. Henry, L.B. Davidson, J.E. Wilson, B.K. McKenna, S.A. Scott, and P.F. McDonagh et al. Whole blood aggregation and coagulation in db/db and ob/ob mouse models of type 2 diabetes Blood Coagul Fibrinolysis 19 2008 124 134
9. M.L. Henry, L.B. Davidson, Z. Cohen, P.F. McDonagh, P.E. Nolan, and L.S. Ritter Whole blood aggregation, coagulation, and markers of platelet activation in diet-induced diabetic C57BL/6 J mice Diabetes Res Clin Pract 84 2009 11 18
10. J.B. Clark, C.J. Palmer, and W.N. Shaw The diabetic Zucker fatty rat Proc Soc Exp Biol Med 173 1983 68 75
11. S.C. Griffen, J. Wang, and M.S. German A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat Diabetes 50 2001 63 68
12. C. Gustavsson, T. Soga, E. Wahlstrom, M. Vesterlund, A. Azimi, and G. Norstedt et al. Sex-dependent hepatic transcripts and metabolites in the development of glucose intolerance and insulin resistance in Zucker diabetic fatty rats J Mol Endocrinol 47 2011 129 143
13. J.P. Corsetti, J.D. Sparks, R.G. Peterson, R.L. Smith, and C.E. Sparks Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats Atherosclerosis 148 2000 231 241
14. C.J. Nolan, P. Damm, and M. Prentki Type 2 diabetes across generations: from pathophysiology to prevention and management Lancet 378 2011 169 181
15. M. Prentki, and C.J. Nolan Islet beta cell failure in type 2 diabetes J Clin Invest 116 2006 1802 1812
16. W. Paul, L.R. Queen, C.P. Page, and A. Ferro Increased platelet aggregation in vivo in the Zucker Diabetic Fatty rat: differences from the streptozotocin diabetic rat Br J Pharmacol 150 2007 105 111
17. G.M. Keating Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation Drugs 73 2013 825 843
18. Y. Xu, W. Wu, L. Wang, M. Chintala, A.S. Plump, and M.L. Ogletree et al. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro Blood Coagul Fibrinolysis 24 2013 332 338
19. M. Chintala, J. Strony, B. Yang, S. Kurowski, and Q. Li SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys Arterioscler Thromb Vasc Biol 30 2010 2143 2149
20. W.A. Schumacher, J.S. Bostwick, A.B. Stewart, T.E. Steinbacher, B. Xin, and P.C. Wong Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis J Cardiovasc Pharmacol 55 2010 609 616
21. R.J. Broersma, L.W. Kutcher, and E.F. Heminger The effect of thrombin inhibition in a rat arterial thrombosis model Thromb Res 64 1991 405 412
22. H.R. Hansen, J.L. Wolfs, L. Bruggemann, D.W. Sommeijer, E. Bevers, and A.D. Hauer et al. Hyperglycemia accelerates arterial thrombus formation and attenuates the antithrombotic response to endotoxin in mice Blood Coagul. Fibrinolysis 18 2007 627 636
23. F.R. Macdonald, J.E. Peel, H.B. Jones, R.M. Mayers, L. Westgate, and J.M. Whaley et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats Diabetes Obes Metab 12 2010 1004 1012
24. S. Han, D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, and S.A. Biller et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats Diabetes 57 2008 1723 1729
25. P.C. Wong, E.J. Crain, B. Xin, R.R. Wexler, P.Y. Lam, and D.J. Pinto et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies J Thromb Haemost 6 2008 820 829
26. P.F. Bodary, R.J. Westrick, K.J. Wickenheiser, Y. Shen, and D.T. Eitzman Effect of leptin on arterial thrombosis following vascular injury in mice JAMA 287 2002 1706 1709
27. S. Konstantinides, K. Schafer, S. Koschnick, and D.J. Loskutoff Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity J Clin Invest 108 2001 1533 1540
28. M. Nakata, T. Yada, N. Soejima, and I. Maruyama Leptin promotes aggregation of human platelets via the long form of its receptor Diabetes 48 1999 426 429
29. C. Dellas, K. Schafer, I.K. Rohm, M. Lankeit, M. Leifheit, and D.J. Loskutoff et al. Leptin signalling and leptin-mediated activation of human platelets: importance of JAK2 and the phospholipases Cgamma2 and A2 Thromb Haemost 98 2007 1063 1071
30. H.J. Beijers, I. Ferreira, H.M. Spronk, B. Bravenboer, J.M. Dekker, and G. Nijpels et al. Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability: potential role of central adiposity and low-grade inflammation-the Hoorn Study Thromb Res 129 2012 557 562
31. L. Ay, F. Hoellerl, C. Ay, J.M. Brix, S. Koder, and G.H. Schernthaner et al. Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease Eur J Clin Invest 42 2012 470 477
32. A. Tripodi, A. Branchi, V. Chantarangkul, M. Clerici, G. Merati, and A. Artoni et al. Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay J Thromb Thrombolysis 31 2011 165 172
33. R.S. El-Hagracy, G.M. Kamal, I.M. Sabry, A.A. Saad, N.F. Abou El Ezz, and H.A. Nasr Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus Oman Med J 25 2010 173 178
34. P.B. Leurs, R.P. Stolk, K. Hamulyak, R. Van Oerle, D.E. Grobbee, and B.H. Wolffenbuttel Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes Diabetes Care 25 2002 1340 1345
35. P. Moreno, and P.J. Ginel Effects of haemolysis, lipaemia and bilirubinaemia on prothrombin time, activated partial thromboplastin time and thrombin time in plasma samples from healthy dogs Res Vet Sci 67 1999 273 276
36. C. Erem Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity Clin Endocrinol 64 2006 323 329
37. B.A. Lemkes, J. Hermanides, J.H. Devries, F. Holleman, J.C. Meijers, and J.B. Hoekstra Hyperglycemia: a prothrombotic factor? J Thromb Haemost 8 2010 1663 1669
38. M. Ono, K. Nawa, and Y. Marumoto Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis Thromb Haemost 72 1994 421 425
39. C.A. Kretz, N. Vaezzadeh, and P.L. Gross Tissue factor and thrombosis models Arterioscler Thromb Vasc Biol 30 2010 900 908
40. W.R. Surin, P. Prakash, M.K. Barthwal, and M. Dikshit Optimization of ferric chloride induced thrombosis model in rats: effect of anti-platelet and anti-coagulant drugs J Pharmacol Toxicol 61 2010 287 291
41. P. Kraft, S.F. De Meyer, and C. Kleinschnitz Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis' J Cereb Blood Flow Metab 32 2012 1831 1840
42. D.J. Angiolillo, and J.L. Ferreiro Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents Am J Cardiovasc Drug 13 2013 233 250